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Introduction 
Glaucoma is the second leading cause of blindness globally 
after cataract.1 Treatment of glaucoma aims to preserve 
visual function and maintain overall quality of life.2 In 
Canada, a model of interprofessional collaboration between 
ophthalmologists and optometrists has been suggested.3 
Management decisions are made based on the mechanism of 
glaucoma, the stage of disease, and the degree of intraocular 
pressure (IOP) elevation. Patients and care partners should 
be approached in an individualized manner, taking into 
account their biopsychosociospiritual (BPSS) profile and 
preferences.4 This approach considers various components 
of health, including systemic biology such as life expectancy, 
psychological factors, socioeconomic considerations, and 
spiritual/cultural values. 
The standard treatment algorithm has typically employed 
medications, laser treatment, and eventually surgery. 
Medications available in Canada include single agents and 
combination agents involving prostaglandin analogues, 
beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, 
and miotics. Laser treatment options include argon laser 
trabeculoplasty, selective laser trabeculoplasty, and in more 
severe cases cyclophotocoagulation. This paper discusses 
surgical options for glaucoma, in particular several newer 
and less invasive techniques. We will be focusing on the 
trabectome, iStent, and endocyclophotocogulation, which are 
ab interno techniques, as well as canaloplasty, an ab externo 
technique. There are already several studies reviewing these 
techniques and any evidence supporting them, and we have 
referenced these works throughout this paper.5–7 
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Glaucoma Surgery: A Brief History
Since the 1950s, we have known that the major site of 
aqueous outflow resistance is the juxtacanalicular portion of 
the trabecular meshwork.8 Efforts were made as early as the 
1950s to perforate this tissue with energy from light sources 
to allow for improved outflow.9 Moses studied microsurgical 
electro cautery techniques to the trabecular meshwork in 
enucleated eyes in 1971.10 Shortly thereafter, laser treatment of 
the trabecular meshwork became well studied and employed. 
Surgery to the angle has been well established in the congenital 
glaucoma population, but it was not until the last fifteen years 
that angle surgery in adults has come into favour.11 
A Review Of The Relevant Anatomy
The aqueous is produced by the ciliary processes and leaves the 
eye by two main pathways: the conventional or trabecular pathway, 
accounting for 70–95% of aqueous egress from the eye, and the 
unconventional or uveoscleral outflow, accounting for the other 
5–30% (see Figure 1).12  The techniques described here will be 
focusing on the aqueous production and trabecular outflow. This 
consists of the trabecular meshwork, Schlemm’s canal, intrascleral 
channels, and the episcleral or conjunctival veins. 
Classification Of Incisional Surgeries For 
Glaucoma  
Incisional glaucoma surgery can be divided into procedures 
that reduce inflow of aqueous and procedures that enhance 
outflow (see Figure 2). Outflow procedures are the most 
common. Currently, trabeculectomy and glaucoma drainage 
devices remain the most frequently used techniques and 
several large-scale studies have demonstrated their efficacy.13–15 
Over the last ten years, there has been a shift towards 
Figure 1.	Aqueous	outflow	pathways.
Figure 2.	Classification	of	Incisional	Glaucoma	Surgery.		*	Gonioscopy-assisted	transluminal	trabeculotomy	
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alternative glaucoma surgeries, largely due to the high rate of 
complications associated with traditional glaucoma surgeries. 
These newer techniques have become known as “micro-
invasive glaucoma surgery,” or MIGS, and play a different role 
in the glaucoma treatment algorithm.5,7,11
Enhancing the Outflow Pathways: 
Trabectome, iStent, and Canaloplasty Trabectome
Description of the Procedure
The Trabectome (Neomedix Corp.) is composed of a 
disposable hand piece that supplies irrigation and aspiration 
and a tip that delivers high-frequency electro cautery. The 
hand piece is advanced across the anterior chamber through 
a temporal corneal incision towards the nasal angle with 
the irrigating fluid on. Under gonioscopic visualization, the 
footplate is inserted into the trabecular meshwork. The cautery 
is activated, and the surgeon advances the instrument in a 
clockwise and counterclockwise manner, thereby removing a 
3–4 clock-hour arc of trabecular meshwork and the inner wall 
of Schlemm’s canal. This effectively creates a direct pathway for 
the aqueous to flow from the anterior chamber to the collector 
channels.6 The procedure is generally combined with cataract 
extraction, although there may be certain subgroups who do 
well with trabectome alone, such as exfoliation syndrome,16 
and juvenile open angle glaucoma.17
The advantages of this procedure over traditional 
glaucoma surgeries include the faster recovery, due to 
the less invasive nature, the approach which leaves the 
conjunctiva intact for future surgeries, the lack of a filtering 
bleb, and the minimal added risk to the patient if combined 
with phacoemulsification.18 The disadvantages are that IOP 
lowering is generally not as substantial as it is with traditional 
glaucoma surgery, and there are some potential complications, 
the most common one being hyphema. This usually clears in a 
few days. Other complications include damage to the cornea, 
iris, or lens, as well as intraocular pressure elevation, but 
serious complications such as hypotony and suphrachoroidal 
hemorrhage are very rare.19 Delayed hyphema has also been 
reported,20 where blood refluxes through the trabectome cleft, 
which usually resolves within a few weeks but can recur.
Evidence
Several studies have evaluated the effectiveness of trabectome, 
the first ones being trabectome alone21 and later ones being 
trabectome combined with phacoemulsification.22 The first 
large study was a noncomparative prospective case series of 
304 eyes with open-angle glaucoma undergoing trabectome 
combined with cataract extraction.22 Mean baseline IOP of 20 
mmHg decreased at 12 months to 15.5 mmHg, and medications 
decreased from 2.65 to 1.76. Secondary glaucoma procedures 
were performed in 9 patients. A retrospective review of 88 cases 
of trabectome alone and 158 cases of combined trabectome 
and cataract from the Mayo Clinic, found a reduction in 
mean IOP from 21.6 mmHg to 15.3 mmHg and a decrease in 
number of glaucoma medications from 3.1 to 1.9 at 2 years. 
However, subsequent glaucoma surgery was required in 66 
patients (26.8%), an average of 10 months after surgery.23 
The weakness of these studies is the lack of a comparison (e.g. 
phacoemulsification alone) to prove the effectiveness of the 
procedure, since prior studies have demonstrated the IOP-
lowering benefit of phacoemulsification alone.24,25
iStent
Description of the Procedure
The Glaukos micro-bypass trabecular iStent (Glaukos Corp.) 
is the smallest medical device to be implanted in the human 
body. It is made of nonferromagnetic heparin coated titanium 
and consists of an inlet (“snorkel”) connected at a right angle 
to the implantable portion (see Figure 3).6 The preloaded iStent 
inserter is advanced across the anterior chamber through a 
temporal corneal incision under gonioscopic visualization 
towards the nasal angle. The sharp tip of the iStent is used 
to engage and perforate the trabecular meshwork, and the 
stent then slides into the Schlemm canal. The device is then 
released from the inserter. Usage of the iStent has been studied 
in combination with cataract extractions. The advantages 
of the iStent are similar to the trabectome in terms of 
minimizing ocular tissue damage, and possibly lower risk of 
complications.26 
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Figure 3.	:	iStent	Trabecular	Microbypass	Stent.	
Courtesy of Glaukos Corporation, Laguna Hills, California, USA.
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Evidence 
Initial studies reported the use of a single iStent per eye, though 
subsequent studies found multiple stents to be more effective.27 
Spiegal et al. reported the successful use of the iStent in 2008 
in a prospective, multicenter noncomparative interventional 
trial.28 Since then, further validation has arisen from 
randomized control trials comparing phacoemulsification 
alone to phacoemulsification with iStents.29–31 In the two-year 
follow-up paper by the iStent Study Group, 240 eyes with mild 
to moderate glaucoma were randomized to receive one iStent 
combined with phacoemulsification or phacoemulsification 
alone. At both one and two years, the proportion of patients 
with unmedicated IOP of 21 or less was significantly higher 
in the iStent group.31 Amount of hypotensive medications 
were lower in the stent group at one year, but this did not 
reach statistical significance at two years. Complication 
rate was similar between the two groups, and there were 
no stent-related adverse effects reported after two years. 
More recently, Ahmed et al. evaluated the use of two iStents 
combined with travaprost post-operatively, to improve both 
conventional trabecular and uveoscleral outflow in 39 open 
angle glaucoma patients uncontrolled on two medications. 
Mean IOP decreased from 22.2 mmHg to 11.8 mmHg at 
18 months, from two medications pre-operatively to one 
medication post-operatively.32 
Further expansion of the iStent’s role and its long-term 
efficacy are yet to be determined. Some authors have suggested 
it may play a limited role in select patients with advanced 
disease or even prior filtering surgery.33,34
Canaloplasty
Description of the Procedure 
This technique is similar in concept to viscocanalostomy, 
which involves the creation of a deep sclerectomy followed by 
injection of viscoelastic into Schlemm’s canal. In canaloplasty, 
a superficial and then deeper scleral flap is created, so that 
Schlemm’s canal can be reached. The canaloplasty device 
(Ellex) contains a fiber optic light catheter that is then inserted 
into one end of the open Schlemm’s canal. This is threaded 
around the canal for 360 degrees, with the aid of the light, such 
that a false passage is not created, until it exits from the other 
opening in Schlemm’s canal. A prolene suture is then attached 
to the distal end of the catheter, and the catheter is withdrawn, 
thereby threading the suture through the canal. The ends of the 
suture are tied to distend the trabecular meshwork. 
The advantages of this procedure are that it does not require 
a filtering bleb, though occasionally one forms,35 and it has less 
complications compared to conventional trabeculectomy. The 
disadvantages are that the learning curve is long, in some cases it 
is impossible to canulate Schlemm’s canal, and the IOP-lowering 
effect is not as dramatic as trabeculectomy.36 It is also more 
invasive than the MIGS procedures, as it disrupts conjunctiva, 
although ab interno approaches are now also being explored.
Evidence 
In a nonrandomized multicentre trial, Lewis et al. reported the 
three-year results of 157 patients undergoing canaloplasty or 
combined canaloplasty-cataract surgery.35 Baseline IOP of 28.5 
mmHg reduced to 15.2 mmHg, and medications decreased 
from 1.8 to 0.8. Most complications occurred intraoperatively 
or in the early post-operative period, including partial suture 
extrusion through the trabecular meshwork, Descemet’s 
detachment, hyphema, and IOP elevation. 
Brüggemann et al. also compared canaloplasty to 
trabeculectomy.37 In this study of 15 patients with prior 
trabeculectomy in one eye, the contralateral eye underwent 
canalopasty, and 6- and 12-month results were compared. 
Both procedures reduced the IOP significantly; however, 
the trabeculectomy group achieved lower IOP (11.64 vs. 
13.21 mmHg), was on no medication, and required fewer 
additional interventions. However, they required longer initial 
hospitalization and more post-operative visits. 
Reducing Inflow: Endoscopic 
Cyclophotocoagulation
Description of the Procedure
Cyclophotocoagulation was first used in the 1970s to lower 
intraocular pressure. It is usually done through a contact 
approach delivered over the area of the ciliary body, thereby 
reducing aqueous production. It is generally left as a last-resort 
to treat end-stage glaucoma due to its unpredictability and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.	:	iStent	Trabecular	Microbypass	Stent.	
Courtesy of Glaukos Corporation, Laguna Hills, California, USA. Figure 4. : Endoscopic Cyclophotocoagulation of the Ciliary Processes. 
Courtesy of Endo Optiks, Inc., Little Silver, New Jersey, USA.
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possibility of complications like phthisis.38 In 1992, however, 
Uram described the use of photocoagulation delivered to the 
ciliary body under direct visualization with endoscopy.39 
Endoscopic cyclophotocoagulation (ECP) has been used in 
several different types of glaucoma, including primary open 
angle, neovascular glaucoma, chronic angle closure, uveitic, 
angle recession,38 and a less destructive version in plateau iris 
syndrome.40 The laser unit contains a probe to deliver the 
diode laser that has a built-in endoscope and attached camera 
monitor. When this is combined with phacoemulsification, 
the ECP is generally done before or after the lens is inserted. 
The probe is inserted through a corneal incision and directed 
behind the iris until the ciliary processes come into view on the 
camera monitor. The laser is then fired with a foot pedal and 
the desired outcome is a whitening of the ciliary processes (see 
Figure 4). This treatment can be done for a circumference of 
90–360 degrees, and a second incision may be required.38 
Evidence 
A retrospective review of 368 eyes that underwent 
phacoemulsification combined with ECP found a 10.9 mmHg 
drop in IOP at two years post-operatively, with a mean decrease 
in number of medications of 1.1.41 The largest published study, 
by the same group, was a retrospective review of 539 patients.42 
All eyes had at least one prior glaucoma surgery and IOP ≥ 
35 on maximal medical therapy or advanced glaucoma with 
IOP above target. The mean IOP decreased from a baseline 
of 38 mmHg to 12.1 mmHg, and an average number of 
medications of 1.9, after 5 years. Prospective studies have also 
evaluated the use of ECP. In a randomized trial, Gayton et al. 
compared ECP to trabeculectomy and found a 29% reduction 
in IOP after ECP vs. 32% following trabeculectomy, with 
similar baseline IOP of 25 mmHg.43 Francis et al. evaluated 
ECP use after failed aqueous shunts. Twent-five eyes received 
ECP for 360 degrees.44 Success, defined as reduction in IOP 
of 3 mmHg and discontinuation of nontolerated glaucoma 
medications, was achieved in 88% of patients up to two years 
follow up. Murthy et al. studied 50 eyes of Indian patients with 
refractory glaucoma, including phakic, pseudophakicm and 
phakic patients, in a prospective non-comparative study.45 IOP 
decreased from 32.58 mmHg to 13.96 mmHg, with an average 
follow up of about one year. The average number of glaucoma 
medications decreased from 2.51 to 1.09.
How To Choose Which Procedure To Use On On 
Each Patient?  
The decision to proceed with glaucoma surgery is a complex 
one that should take into account different ocular and systemic 
factors. In the Canadian model, where optometrists and 
ophthalmologists work together in the best interest of patients, 
effective and timely communication is essential.3,46 Treatment 
of glaucoma and glaucoma suspects is well summarized in 
the Canadian Ophthalmological Society evidence-based 
clinical practice guidelines for the management of glaucoma 
in the adult eye.2 Indications for surgery include situations 
where other methods of lowering IOP have been unsuccessful 
and the optic nerve is failing or likely to fail. Furthermore, 
surgery should be considered when patients are intolerant 
to and/or non-compliant with medications. Referral to an 
ophthalmologist when progression is suspected is crucial in 
preventing glaucoma-related blindness.
The indications for some of the novel glaucoma surgeries 
described here are currently in evolution. The procedures that 
act by increasing outflow (trabectome, iStent, canaloplasty) 
have primarily been studied in the context of mild to moderate 
glaucoma and are usually combined with cataract surgery. Since 
they generally do not lower IOP to a level as low as traditional 
surgery, the authors favour their use in situations where there is 
a visually significant cataract and early or moderate glaucoma 
where the IOP is above target. ECP, however, may be a good 
option in more advanced or refractory glaucoma based on the 
available literature.
Other factors that might encourage a surgeon to proceed 
with a MIGS over a trabeculectomy or tube shunt include poor 
conjunctival or scleral tissue, where a trabectome or iStents 
would be safer than an external surgery, as well as risk factors 
for over-filtration (e.g. myopia) or suprachoroidal hemorrhage 
(e.g. older age, presence of hypertension, use of anticoagulants). 
Fortunately, most MIGS procedures do not seem to affect the 
future outcome of traditional glaucoma surgery.47 Finally, 
patients and care partners should be involved in the discussion 
and decision-making regarding treatment.
Post-Operative Care
Post-operative care for microinvasive glaucoma surgeries 
is similar to post-operative cataract care; however, there are 
several added complications that should be watched for. 
Uveitis may be more prominent due to the added intraocular 
manipulation, in particular with ECP.38 This can usually be 
managed with steroid drops and/or non-steroidal agents, 
especially to reduce the risk of cystoid macular edema. 
Hyphema or microhyphema is not uncommon and can be 
treated conservatively with steroid drops, reduced level of 
activity, and elevation of the head. If a hyphema is large (i.e. 
over one-half of the anterior chamber), not clearing after 
two weeks, or associated with elevated intraocular pressure, 
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consideration should be given to a surgical washout. 
Intraocular pressure elevation may occur, with early 
pressure rise likely due to inflammation and later rise more 
likely from steroid usage, particularly after trabectome 
(author’s personal experience) or iStent surgery.48 The 
management of these two situations, therefore, differs. If the 
inflammatory response seems prominent, steroids should 
be increased; however, if steroid-induced pressure elevation 
is suspected and inflammation is minimal, lower-potency 
steroids or non-steroidal agents should be used and rapidly 
tapered off. 
Since some of these procedures include the insertion of 
a device, there is also the potential for such device-related 
complications as obstruction or malposition, though these risks 
are low.5 Gonioscopy may be necessary to identify these issues. 
Finally, as is the case with all glaucoma surgeries, the pressure 
control may decrease or fail over time, at which point other 
methods must be employed (drops, laser, further surgery).
Conclusion And Summary
Surgical care of glaucoma is undergoing some major paradigm 
shifts. Larger scale randomized control trials will be important 
in better defining the role of MIGS in the treatment algorithms. 
Other MIGS procedures not discussed here have also been 
described, including Hydrus, CyPass, iStent inject (second-
generation iStent), as well as other newer surgical treatments 
such as the Gold shunt. Finally, modifications of conventional 
surgeries have been studied and employed by many, including 
the Ex-PRESS Glaucoma Filtration Device (Alcon, Inc.), as 
an additive device to traditional trabeculectomy surgery. 
With continued collaboration among eye care specialists, 
individualized glaucoma care is becoming a reality. 
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Co-Management:
Your patients come f irst! 
Our Co-Management program oers many advantages: 
Book your free consultation at 1-877-793-1515 or at lasikmd.com 
Direct access to our team:  comanagement@lasikmd.com 
30 clinics across Canada
LASIK MD annually performs over 
60% of all laser vision correction 
procedures in Canada
More than 10 years of experience 
Experienced surgeons who have 
collectively performed over 750,000 
procedures†
Aordable prices for your patients 
starting at $490 per eye* 
†Based on the collective experience of all LASIK MD surgeons. *Prices are subject to change without prior notice and vary based on prescription strength. Only applicable on a procedure for both eyes. Other conditions may 
apply.
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